TARGET PharmaSolutions, Inc., has announced that it has entered into a strategic partnership with Gilead Sciences for TARGET-NASH and TARGET-HBV.
Gilead is the sixth partner in TARGET-NASH, joining Allergan, Boehringer Ingelheim, Bristol-Myers Squibb, Intercept and Novartis, and the first partner to join TARGET-Hepatitis B. The TARGET model also provides its stakeholders access to a biorepository linked to validated clinical outcomes, including patient reported outcomes.
TARGET PharmaSolutions, founded in 2015, headquartered in Chapel Hill, North Carolina, USA, is a privately held real-world data solutions company that provides pharmaceutical and biotechnology partners a more efficient way to generate data in the real-world setting.
TARGET PharmaSolutions has six disease communities: TARGET-NASH (nonalcoholic steatohepatitis), TARGET-PBC (primary biliary cholangitis), TARGET-HCC (hepatocellular carcinoma), TARGET-IBD (inflammatory bowel disease), TARGET-DERM (immune mediated skin conditions) and TARGET-HBV (hepatitis B).
Gilead Sciences is a biopharmaceutical company founded in 1987, headquartered in Foster City, California, USA, with a market capitalization of approximately USD $86 billion as of November 23, 2018. Notably, the company brought one of the first cellular therapies for cancer to market in 2017, following the acquisition of Kite Pharma.
TARGET-NASH is a robust, meticulously-documented, longitudinal observational study that evaluates adult and pediatric patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
TARGET-NASH has enrolled over 4,250 patients to date and will enroll up to 15,000 patients in total over the coming years. TARGET-NASH is led by an academic steering committee chaired by Drs. Arun Sanyal, MD (Virginia Commonwealth University); Ken Cusi, MD (University of Florida), and Brent Tetri (Saint Louis University).
TARGET-HBV is an observational study that is evaluating patients with Hepatitis B. TARGET-HBV recently started enrolling patients and plans to enroll up to 5,000 patients across a diverse network of sites to advance understanding of Hepatitis B.
“TARGET-NASH is critical for the scientific and regulatory community as we prepare for the plethora of new agents for the treatment of NASH. In the immediate term, it will give us a critical understanding of NASH diagnosis and management in the real world across multiple populations. In the longer term, it is the perfect platform to have a deep understanding of the safety and effectiveness of these new agents across populations not included or underrepresented in Phase 3 clinical trials.” – Dr. Arun Sanyal, MD, the academic steering committee co-chair
“We are very excited to have Gilead join TARGET-NASH and TARGET-HBV. It is a privilege to partner with a company so focused on advancing the understanding of Liver Diseases.” – Meg Powell, Pharm.D., CEO of TARGET PharmaSolutions